Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Background To characterize genomic determinants of response to pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 study. Methods Associations between biomarkers (tumor mutational burden (TMB), neoantigen load (NL), 18-gene T-cell-inflamed gen...

Full description

Bibliographic Details
Main Authors: Albright, A. (Author), Ayers, M. (Author), Burtness, B. (Author), Cheng, J. (Author), Chow, L.Q.M (Author), Cristescu, R. (Author), Eder, J.P (Author), Gluck, I. (Author), Gupta, S. (Author), Haddad, R.I (Author), Huang, L. (Author), Kang, H. (Author), Keam, B. (Author), Lunceford, J. (Author), Mehra, R. (Author), Mogg, R. (Author), Muro, K. (Author), Seiwert, T.Y (Author), Tahara, M. (Author), Weiss, J. (Author)
Format: Article
Language:English
Published: BMJ Publishing Group 2022
Subjects:
Online Access:View Fulltext in Publisher